Lyra Therapeutics announces $50M private placement; extends cash runway into Q1 2025

Lyra Therapeutics, Inc.

Gross proceeds of ~$50M from sale of ~17.7M shares, ~2.4M pre-funded warrants, and ~10.0M purchase warrants at $2.4925 per unit.
Pre-funded warrants exercisable immediately at $0.001/share, expire May 2028; purchase warrants exercisable from Nov 2023 at $2.673/share, expire Nov 2028.
Cash, cash equivalents and short-term investments stood at $82.7M as of Q1 2023; combined with net proceeds expected to fund operations into Q1 2025.
Cantor Fitzgerald and William Blair acted as joint lead placement agents; H.C. Wainwright as co-placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lyra Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at aggregate gross proceeds of approximately $50.0 million (effective 2023-05-25).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers named therein
Value: aggregate gross proceeds of approximately $50.0 million
Effective: 2023-05-25

Exact text from the filing

On May 25, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to sell securities to the Investors in a private placement (the “Private Placement”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-157998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.